52 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
PACB Pacific Biosciences of California, Inc. $5.14 $678.18M N/A
Article Searches
Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock? http://www.zacks.com/stock/news/293114/are-options-traders-betting-on-a-big-move-in-pacific-biosciences-pacb-stock?cid=CS-ZC--293114 Feb 21, 2018 - Surging implied volatility makes Pacific Biosciences (PACB) stock lucrative to the option traders.
What's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales https://www.fool.com/investing/2018/02/02/whats-behind-pacific-biosciences-of-californias-si.aspx?source=iedfolrf0000001 Feb 02, 2018 - The gene-sequencing company didn't have much good news from the fourth quarter, but better days could be ahead.
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up http://www.zacks.com/stock/news/291186/pacific-biosciences-pacb-q4-loss-narrows-consumables-up?cid=CS-ZC-FT-291186 Feb 02, 2018 - Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Pacific Biosciences of California's (PACB) CEO Michael Hunkapiller on Q4 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4142462-pacific-biosciences-californias-pacb-ceo-michael-hunkapiller-q4-2017-results-earnings-call?source=feed_sector_healthcare Feb 01, 2018 - Pacific Biosciences of California Inc. (NASDAQ:PACB) Q4 2017 Earnings Conference Call February 01, 2018 04:30 PM ET Executives Trevin Rard - Investor Relations Michael Hunkapiller - President and Chie
Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock http://www.zacks.com/stock/news/290361/options-traders-expect-huge-moves-in-pacific-biosciences-pacb-stock?cid=CS-ZC--290361 Jan 29, 2018 - Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.
Here's Why Pacific Biosciences of California Is Surging Today https://www.fool.com/investing/2018/01/25/heres-why-pacific-biosciences-of-california-is-sur.aspx?source=iedfolrf0000001 Jan 25, 2018 - Another big purchase order for the genome sequencing equipment manufacturer ahead of its full-year 2017 earnings report is just what investors wanted to see.
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings? http://www.zacks.com/stock/news/289856/whats-in-store-for-pacific-biosciences-pacb-in-q4-earnings?cid=CS-ZC-FT-289856 Jan 24, 2018 - Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.
Is Illumina, Inc. a Buy in 2018? https://www.fool.com/investing/2018/01/18/is-illumina-inc-a-buy-in-2018.aspx?source=iedfolrf0000001 Jan 18, 2018 - This gene-sequencing stock soared in 2017. But can its momentum continue in the new year?
Pacific Biosciences of California (PACB) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow https://seekingalpha.com/article/4136696-pacific-biosciences-california-pacb-presents-36th-annual-j-p-morgan-healthcare-conference?source=feed_sector_healthcare Jan 10, 2018 - The following slide deck was published by Pacific Biosciences of California in conjunction with this event.
Pacific Biosciences Hurt by Competition in Niche Markets http://www.zacks.com/stock/news/288400/pacific-biosciences-hurt-by-competition-in-niche-markets?cid=CS-ZC-FT-288400 Jan 10, 2018 - Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.

Pages: 123456

<<<Page 3>